Trial Profile
A Randomized, Double-Blind, Double-Dummy, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of Oral Once-Daily Administration of TAK-438, 10 or 20 mg Compared to Lansoprazole 15 mg in the Maintenance Treatment of Subjects With Endoscopic Healing of Erosive Esophagitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Vonoprazan (Primary) ; Lansoprazole
- Indications Erosive oesophagitis
- Focus Registrational; Therapeutic Use
- Sponsors Takeda
- 13 Oct 2020 Results of sub group analysis evaluating the non-inferiority of vonoprazan compared to lansoprazole in the maintenance phase of healed EE in Chinese patients presented at the 28th United European Gastroenterology Week
- 19 May 2020 Primary endpoint has been met. (Percentage of Participants with Recurrence of Erosive Esophagitis as Confirmed on Endoscopy after the 24-week Maintenance Phase)
- 19 May 2020 Results published in Gasteroenterology in conjunction with Digestive Disease Week 2020.